These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 39143312)

  • 1. Adherence, Persistence, Healthcare Resource Use, and Costs in Tofacitinib-Treated Patients with Psoriatic Arthritis: Data from Two United States Claims Databases.
    Mease PJ; Papademetriou E; Potluri R; Agarwal E; Cappelleri JC; Ling YL
    Adv Ther; 2024 Oct; 41(10):3850-3867. PubMed ID: 39143312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early Real-World Experience of Tofacitinib for Psoriatic Arthritis: Data from a United States Healthcare Claims Database.
    Mease PJ; Young P; Gruben D; Fallon L; Germino R; Kavanaugh A
    Adv Ther; 2022 Jun; 39(6):2932-2945. PubMed ID: 35482248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial Experience With Tofacitinib in Clinical Practice: Treatment Patterns and Costs of Tofacitinib Administered as Monotherapy or in Combination With Conventional Synthetic DMARDs in 2 US Health Care Claims Databases.
    Harnett J; Curtis JR; Gerber R; Gruben D; Koenig A
    Clin Ther; 2016 Jun; 38(6):1451-1463. PubMed ID: 27112534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment patterns and health care costs among patients with psoriatic arthritis treated with biologic or targeted synthetic disease-modifying antirheumatic drugs.
    Murage MJ; Princic N; Park J; Malatestinic WN; Zhu B; Atiya B; Kern SA; Stenger KB; Sprabery AT; Ogdie A
    J Manag Care Spec Pharm; 2022 Feb; 28(2):206-217. PubMed ID: 35098751
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis.
    Wu JJ; Pelletier C; Ung B; Tian M; Khilfeh I; Curtis JR
    Adv Ther; 2020 May; 37(5):2098-2115. PubMed ID: 32141018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Costs and Health Outcomes Associated with Tofacitinib Treatment for Active Psoriatic Arthritis in the United States.
    Bungey G; Chang-Douglass S; Hsu MA; Cappelleri JC; Young P; Woolcott J
    J Manag Care Spec Pharm; 2020 Aug; 26(8):1027-1038. PubMed ID: 32308099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Real-World Experience with Tofacitinib Compared with Adalimumab, Etanercept, and Abatacept in RA Patients with 1 Previous Biologic DMARD: Data from a U.S. Administrative Claims Database.
    Harnett J; Gerber R; Gruben D; Koenig AS; Chen C
    J Manag Care Spec Pharm; 2016 Dec; 22(12):1457-1471. PubMed ID: 27882833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis.
    Rubin DT; Mittal M; Davis M; Johnson S; Chao J; Skup M
    J Manag Care Spec Pharm; 2017 Aug; 23(8):859-867. PubMed ID: 28737994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment patterns and health care costs for patients with psoriatic arthritis on biologic therapy: a retrospective cohort study.
    Zhu B; Edson-Heredia E; Gatz JL; Guo J; Shuler CL
    Clin Ther; 2013 Sep; 35(9):1376-85. PubMed ID: 23954091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis After Methotrexate or After 1 or 2 TNF Inhibitors from a U.S. Payer Perspective.
    Claxton L; Taylor M; Soonasra A; Bourret JA; Gerber RA
    J Manag Care Spec Pharm; 2018 Oct; 24(10):1010-1017. PubMed ID: 29897007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA.
    Chastek B; Chen CI; Proudfoot C; Shinde S; Kuznik A; Wei W
    Adv Ther; 2017 Nov; 34(11):2422-2435. PubMed ID: 29039054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Retrospective Cohort Study Comparing Utilization and Costs of Biologic Therapies and JAK Inhibitor Therapy Across Four Common Inflammatory Indications in Adult US Managed Care Patients.
    Chastek B; White J; Van Voorhis D; Tang D; Stolshek BS
    Adv Ther; 2016 Apr; 33(4):626-42. PubMed ID: 26970958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis: Modeling the Cost of Treatment Strategies in the United States.
    Claxton L; Jenks M; Taylor M; Wallenstein G; Mendelsohn AM; Bourret JA; Singh A; Moynagh D; Gerber RA
    J Manag Care Spec Pharm; 2016 Sep; 22(9):1088-102. PubMed ID: 27579831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment Patterns and Costs in Biologic DMARD-Naive Patients with Rheumatoid Arthritis Initiating Etanercept or Adalimumab with or Without Methotrexate.
    Tkacz J; Gharaibeh M; DeYoung KH; Wilson K; Collier D; Oko-Osi H
    J Manag Care Spec Pharm; 2020 Mar; 26(3):285-294. PubMed ID: 32105179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic Benefit from Improvements in Quality of Life with Upadacitinib: Comparisons with Tofacitinib and Methotrexate in Patients with Rheumatoid Arthritis.
    Bergman M; Tundia N; Yang M; Orvis E; Clewell J; Bensimon A
    Adv Ther; 2021 Dec; 38(12):5649-5661. PubMed ID: 34636000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden-a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs.
    Strand V; de Vlam K; Covarrubias-Cobos JA; Mease PJ; Gladman DD; Graham D; Wang C; Cappelleri JC; Hendrikx T; Hsu MA
    RMD Open; 2019; 5(1):e000806. PubMed ID: 30713721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient Support Program Increased Medication Adherence with Lower Total Health Care Costs Despite Increased Drug Spending.
    Brixner D; Rubin DT; Mease P; Mittal M; Liu H; Davis M; Ganguli A; Fendrick AM
    J Manag Care Spec Pharm; 2019 Jul; 25(7):770-779. PubMed ID: 31081461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.
    Ogdie A; de Vlam K; McInnes IB; Mease PJ; Baer P; Lukic T; Gruben D; Kwok K; Wang C; Hsu MA; Maniccia A
    RMD Open; 2020 Feb; 6(1):. PubMed ID: 32396519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriatic arthritis: results from a US claims analysis.
    Wu JJ; Pelletier C; Ung B; Tian M
    Curr Med Res Opin; 2020 Jan; 36(1):169-176. PubMed ID: 31517542
    [No Abstract]   [Full Text] [Related]  

  • 20. Radiographic Progression According to Baseline C-reactive Protein Levels and Other Risk Factors in Psoriatic Arthritis Treated with Tofacitinib or Adalimumab.
    van der Heijde D; Gladman DD; FitzGerald O; Kavanaugh A; Graham D; Wang C; Fallon L
    J Rheumatol; 2019 Sep; 46(9):1089-1096. PubMed ID: 30824647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.